Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma - Galapagos (NASDAQ:GLPG)
Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicinesAims to preserve the Jyseleca® (filgotinib) business and a